Cytokine therapy reverses NK cell anergy in MHC-deficient tumors

Various cytokines have been evaluated as potential anticancer drugs; however, most cytokine trials have shown relatively low efficacy. Here, we found that treatments with IL-12 and IL-18 or with a mutant form of IL-2 (the "superkine" called H9) provided substantial therapeutic benefit for...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of clinical investigation 2014-11, Vol.124 (11), p.4781-4794
Hauptverfasser:	Ardolino, Michele, Azimi, Camillia S, Iannello, Alexandre, Trevino, Troy N, Horan, Lucas, Zhang, Lily, Deng, Weiwen, Ring, Aaron M, Fischer, Suzanne, Garcia, K Christopher, Raulet, David H
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antigens, Neoplasm - genetics Antineoplastic Agents - pharmacology Biomedical research Care and treatment Cell Line, Tumor Clinical trials Clonal Anergy Cytokines Experiments Flow cytometry Health aspects Histocompatibility Antigens Class I - genetics Histocompatibility Antigens Class I - metabolism Humans Immune system Immunotherapy Interleukin-12 - pharmacology Interleukin-18 - pharmacology Interleukin-2 - pharmacology Killer cells Killer Cells, Natural - drug effects Killer Cells, Natural - immunology Lymphoma Major histocompatibility complex Major Histocompatibility Complex - genetics Medical research Melanoma Mice, Inbred C57BL Neoplasm Transplantation Physiological aspects Studies Surveillance Tumor Escape Tumors Women Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!